A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset

Journal of Rheumatology

Volumn 39, Issue 6, 2012, Pages 1241-1247

  Mendoza, Fabian A ^a   Nagle, Sarah J ^a   Lee, Jason B ^b   Jimenez, Sergio A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Dermopathology Division   (United States)

Author keywords

Fibrosis; Mycophenolate mofetil; Scleroderma; Systemic slerosis; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA SMOOTH MUSCLE ACTIN; ANTINUCLEAR ANTIBODY; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN; COLLAGEN TYPE 14A1; COLLAGEN TYPE 1A1; COLLAGEN TYPE 1A2; COLLAGEN TYPE 4A1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA DIRECTED RNA POLYMERASE; DNA DIRECTED RNA POLYMERASE III; FIBRONECTIN; FIBRONECTIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTON PUMP INHIBITOR; SCL 70 ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ACTA2 GENE; ADULT; ARTICLE; BODY SURFACE; CAUSE OF DEATH; CLINICAL ARTICLE; COL14A1 GENE; COL1A1 GENE; COL1A2 GENE; COL4A1 GENE; CONTROLLED STUDY; CTGF GENE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG FATALITY; DRUG TOLERABILITY; FN1 GENE; GASTROINTESTINAL SYMPTOM; GENE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LOW DRUG DOSE; LUNG FUNCTION TEST; LYMPHOCYTOPENIA; MEDSGER SEVERITY SCORE; MODIFIED RODNAN SKIN SCORE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN EXAMINATION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TGFB1 GENE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

DISEASE PROGRESSION; FIBRILLAR COLLAGENS; FIBROSIS; GENE EXPRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; MIDDLE AGED; MYCOPHENOLIC ACID; PROGNOSIS; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; SCLERODERMA, DIFFUSE; SKIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861821762     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111229     Document Type: Article

References (31)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
2. Wei J, Bhattacharyya S, Tourtellotte WG, Varga J. Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy. Autoimmun Rev 2011;10:267-75.
3. Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol 2011;6:509-37.
4. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990,113:352-7. (Pubitemid 20262820)
5. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203. (Pubitemid 29268956)
6. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, et al. Recombinant human anti-transforming growth factor beta-1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33. (Pubitemid 46106206)
7. Pope, JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
8. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-72.
9. Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:299-305. (Pubitemid 29072847)
10. Cellcept prescribing information. Genentech USA Inc. (Rev Feb 2010). [Internet. Accessed March 20, 2012.] Available from: www.cellcept.com/cellcept/
11. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
12. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010;77:152-60.
13. Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 2007;321:583-9. (Pubitemid 46624497)
14. Petrova DT, Brandhorst G, Brehmer F, Gross O, Oellerich M, Armstrong VW. Mycophenolic acid displays IMPDH-dependent and IMPDH-independent effects on renal fibroblast proliferation and function. Ther Drug Monit 2010;32:405-12.
15. Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C, et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant history. Kidney Int 2000;58:51-61. (Pubitemid 30429849)
16. Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E, et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007;25:287-92. (Pubitemid 46851433)
17. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis - A retrospective analysis. Rheumatology 2007;46:442-5. (Pubitemid 46344656)
18. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008;133:455-60. (Pubitemid 351272405)
19. Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology 2009;48:1595-9.
20. Le EN, Wigley FM, Shah AA, Boin F, Hummers LK. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011;70:1104-7.
21. Herrick AL, Lunt M, Whidby N, Ennis H, Silman A, McHugh N, et al. Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 2010;37:116-24.
22. Derk CT, Huaman G, Jimenez SA. A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. Br J Dermatol 2008;158:1063-8. (Pubitemid 351521424)
23. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: Development and testing. J Rheumatol 1999;26:2159-67. (Pubitemid 29487010)
24. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
25. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5. (Pubitemid 18073738)
26. Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60:1102-11.
27. Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, et al. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 2008;58:1810-22. (Pubitemid 351847536)
28. Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepiz GE. Scleroderma lung: Initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006;55:598-602. (Pubitemid 44289880)
29. Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Selva-O'Callaghan A, Solans-Laqué R, Vilardell-Tarrés M. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 2011;30:1398-8.
30. Furst DE, Tseng CH, Clements PJ, Strange C, Tashkin DP, Roth MD, et al. Adverse events during the Scleroderma Lung Study. Am J Med 2011;124:459-67.
31. Binks M, Passweg JR, Furst DE, McSweeney P, Sullivan K, Besenthal C, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease. Ann Rheum Dis 2001;60:577-84. (Pubitemid 32493984)